No Association between Single-Nucleotide Polymorphisms of The S1PR1 Gene or Interleukin-17 Levels with Fingolimod Response in A Small Group of Iranian Relapsing-Remitting Multiple Sclerosis Patients: A Case-Control Study
Objective: Multiple sclerosis (MS) has a multi-factorial etiology involving genetic factors. Fingolimod (Gilenya ®,FTY720) modulates the G-protein-coupled sphingosine 1-phosphate (S1P) receptors, S1PR1, 2, 3, 4 and 5. Variationin the human S1PR1 coding sequence results in heterogeneity in the functi...
Main Authors: | Nasrin Moheghi, Payam Sasannezhad, Andrew John Walley |
---|---|
Format: | Article |
Language: | English |
Published: |
Royan Institute (ACECR), Tehran
2024-03-01
|
Series: | Cell Journal |
Subjects: | |
Online Access: | https://www.celljournal.org/article_711247_4c6fdd2bdb75181aa3ed10ff0ce774ad.pdf |
Similar Items
-
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01) -
The effect of Fingolimod on patients with moderate to severe COVID‐19
by: Soheil Teymouri, et al.
Published: (2023-02-01) -
A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis
by: Claudia Fracasso, et al.
Published: (2022-06-01) -
Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases
by: Sara Grassi, et al.
Published: (2019-07-01) -
Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
by: Ryoko Fukai, et al.
Published: (2019-07-01)